ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
ZVSA Stock Chart & Stats
$0.13
-$0.05(-3.87%)
At close: 4:00 PM EST
$0.13
-$0.05(-3.87%)
Day’s Range― - ―
52-Week Range$0.11 - $1.94
Previous CloseN/A
Volume38.43K
Average Volume (3M)51.59K
Market Cap
$1.62M
Enterprise Value-$100.16M
Total Cash (Recent Filing)$101.78M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap-61.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-Stage PipelineZyVersa’s concentrated R&D focus on renal and inflammatory disorders (FSGS, VAR 200 antibody, IC 100 small molecule) creates a clear strategic roadmap. Specialization in high-unmet-need indications can produce durable value if clinical proof-of-concept is achieved and preserves resource allocation efficiency.
Low Reported LeverageReported low debt reduces fixed financing costs and interest burden, giving management strategic flexibility to time dilutive financings or partnerships. For a pre-revenue biotech, limited debt is a durable advantage when navigating multi-stage clinical development and potential future capital raises.
Secured Near-Term FinancingThe $1M convertible note financing extends runway and signals access to capital sources; registration commitments and anti-dilution features improve investor alignment. This structural financing event materially reduces immediate funding risk and supports continuity of trials and operations over the coming months.
Bears Say
Pre-Revenue With Accelerating LossesBeing pre-revenue leaves the company entirely reliant on external capital while operating losses worsened sharply in 2025. This persistent negative operating performance increases the probability of repeated financings and raises execution risk for multi-year clinical programs without an internal revenue cushion.
Deeply Negative Stockholders' EquityMaterially negative equity indicates erosion of the capital base and reduces financial flexibility. Over the medium term this constrains access to non-dilutive financing, weakens negotiating leverage with partners, and elevates the risk that future capital must be raised on dilutive terms or via onerous securities.
Consistent And Rising Cash BurnSustained negative operating and free cash flow, with a large step-up in 2025, creates ongoing funding pressure. Structurally high cash burn increases the frequency and size of capital raises required, heightening dilution risk and potentially forcing reprioritization or slowdown of clinical programs if new funds are constrained.
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.11 and its highest was $1.94 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $1.62M.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 44 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on Mar 31, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.43.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
6.64%
Insiders
<0.01% Other Institutional Investors
93.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---